Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ionis licenses to Akcea global rights to inotersen in $1.7bn deal
Ionis Pharmaceuticals has licensed to Akcea Therapeutics worldwide rights to inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx, in a transaction potentially worth about $1.7bn.
Research & Development
-
16 Mar 2018
-
07 Nov 2017
Recursion Pharmaceuticals uses Splunk machine learning to treat genetic diseases
Biotechnology company Recursion Pharmaceuticals is using Splunk Enterprise and the Splunk Machine Learning Toolkit to reach its target of treating 100 molecular genetic diseases by 2025.
-
13 Sep 2017
Summit Therapeutics awarded BARDA contract to develop Ridinilazole for CDI
Summit Therapeutics announces that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government's Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, has awarded Summit a contract worth up to $62m.